PK model [Regulatives / Guidelines]

posted by PharmCat  – Russia, 2020-09-10 20:12 (403 d 15:25 ago) – Posting: # 21915
Views: 2,291

Hi Helmut!

I can be wrong.

I suppose when we have modified release dosage form there are can be some changes in the PK model. We shold take in to accaunt that dissolution profile of form in GI can have own dynamic. For example: if absorbtion of dissoluted drug is high and dissolution is linear we can have something with "plato" profile. So resulting PK profile can be wery surprising.

Complete thread:

Activity
 Admin contact
21,739 posts in 4,546 threads, 1,543 registered users;
online 4 (0 registered, 4 guests [including 1 identified bots]).
Forum time: Tuesday 11:38 CEST (Europe/Vienna)

Sometimes the key to an answer is found
in the way you formulate the question.    David Brin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5